Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Lorigan, Paul C
Nathan, P D
James, M G
Strauss, U P
Gore, M E
AffiliationDepartment of Oncology (R4), Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractThe safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study.
CitationSorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. 2011, 105 (3):353-9 Br. J. Cancer
JournalBritish Journal of Cancer
PubMed Central IDPMC3172912